Chemotherapeutic Agent clinical trials

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This study is for children and young people under 25 with a type of brain tumour called low-grade glioma. It compares a new medicine, tovorafenib, with standard chemotherapy to see which works best and is safest for those needing first-time treatment.